Endocrine Society member Joshua Klopper, MD, has been appointed medical director of Endocrinology at the genomic diagnostics company Veracyte. Klopper is a nationally recognized endocrinologist who specializes in the evaluation and management of thyroid nodules and thyroid cancer. He joins Veracyte today, reporting to another Society member, Richard T. Kloos, MD, Veracyte’s executive medical director.
“Dr. Klopper is an exceptional addition to Veracyte’s world-class medical team,” Kloos says. “He was an investigator on the study that demonstrated the clinical utility of our original Afirma genomic classifier for reducing unnecessary surgeries in thyroid nodule evaluation, so is extremely knowledgeable about the test and its clinical value. More broadly, his extensive clinical and research experience, particularly in thyroid nodule and thyroid cancer management, will help us achieve our vision of improving outcomes for patients all over the world at every step of their journey.”
“Over the course of my nearly 20 years providing care for patients with thyroid nodules and thyroid cancer, I’ve witnessed the growing, positive impact of genomic information and technologies”
Klopper most recently served as regional service chief of the Colorado Permanente Medical Group (CPMG) of Kaiser Permanente. Prior to his work at CPMG, Klopper was a full-time faculty member in the Division of Endocrinology at the University of Colorado School of Medicine, where he specialized in thyroid nodule and thyroid cancer evaluation and management. Klopper was the co-director of the Endocrine Society Introductory Hands-On Thyroid Ultrasound Workshop for five years and has served on the American Thyroid Association board of directors.
Klopper graduated from the Emory University School of Medicine. He completed his internship and residency in internal medicine at the University of Colorado Health Sciences Center (UCHSC). He subsequently completed both a postdoctoral research fellowship in the Endocrinology Division of UCHSC and an endocrinology fellowship.
“Over the course of my nearly 20 years providing care for patients with thyroid nodules and thyroid cancer, I’ve witnessed the growing, positive impact of genomic information and technologies,” Klopper says Klopper. “I am thrilled to join the truly impressive medical team at Veracyte, a company that is leading the way in this area to improve patient outcomes and the standard of care.”